Diltiazem and Blood Thinners: Increased Bleeding Risk for Atrial Fibrillation Patients

Patients with atrial fibrillation (AF) who seize the calcium channel blocker diltiazem in combination with direct oral anticoagulants (DOACs) like apixaban or rivaroxaban may face a significantly higher risk of serious bleeding events compared to those taking metoprolol, a beta-blocker. Recent research highlights a crucial drug interaction that clinicians demand to be aware of when managing AF patients.

The Drug Interaction: Diltiazem and DOACs

Diltiazem is known to inhibit cytochrome P450 3A4 and P-glycoprotein, enzymes involved in the metabolism of factor Xa inhibitors – a class of DOACs that includes apixaban and rivaroxaban. This inhibition can lead to increased concentrations of the DOAC in the bloodstream, potentially predisposing patients to bleeding complications.

Research Findings: Increased Bleeding Risk

A retrospective cohort study published in JAMA in April 2024 demonstrated a higher rate of significant bleeding in AF patients concurrently using diltiazem and a DOAC compared to those using metoprolol with a DOAC. The study, involving over 204,000 Medicare beneficiaries, adjusted for various factors to isolate the effect of diltiazem.

Further research, including a study published in the Journal of the American Heart Association, found a 56% higher risk of bleeding-related hospitalization with the combined utilize of diltiazem and DOACs (rivaroxaban, apixaban, or dabigatran). This increased risk was consistent even in patients with and without chronic kidney disease.

A separate study showed that the risk for bleeding events increased with higher doses of diltiazem. Specifically, doses exceeding 120 mg/day were associated with a more pronounced increase in bleeding risk.

What This Means for Patients and Clinicians

These findings underscore the importance of careful consideration when prescribing rate-controlling agents for AF patients already taking DOACs. Clinicians should:

• Assess for potential drug-drug interactions with DOAC medications.
• Consider alternative rate-controlling agents in AF, such as metoprolol, when appropriate.
• Monitor patients closely for signs of bleeding if diltiazem and a DOAC are co-prescribed.

Key Takeaways

• Concurrent use of diltiazem with apixaban or rivaroxaban is associated with an increased risk of serious bleeding.
• The risk is higher with diltiazem doses exceeding 120 mg/day.
• Metoprolol may be a safer alternative rate-controlling agent for patients on DOACs.
• Clinicians should carefully evaluate the risks and benefits of co-prescribing diltiazem and DOACs.

This research emphasizes the need for vigilant medication management in AF patients to minimize the risk of potentially life-threatening bleeding events.